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Imaging dopamine neurotransmission in
Parkinson’s disease: biomarker versus 
surrogate end point
Imaging of dopamine (DA) neurotransmission in
Parkinson’s disease (PD) began with positron emission
tomography (PET) measurements of dopamine synthe-
sis using [
18F]fluorodopa (FDOPA). This precursor is
converted within DA neurons to the ionically charged
[
18F]fluorodopamine, and this radioactive metabolite is
trapped within the cell.The rate of trapping is propor-
tional to the amount of converting enzyme (DOPA
decarboxylase),which itself is correlated with the num-
ber of DA terminals in the striatum.
Two other targets were subsequently imaged as bio-
markers for DA neurotransmission: dopamine trans-
mitter (DAT) and vesicular monoamine transporter,
type 2 (VMAT2). DAT is located on the terminals of
DA neurons in the striatum and functions to remove DA
from the synapse to the intracellular space for recycling
or metabolism.VMAT2 is located on the vesicle mem-
branes of DA and noradrenergic neurons,and transports
intracellular DA (or norepinephrine) into the vesicle,
which is subsequently released by exocytosis on electri-
cal stimulation.DA synthesis and VMAT2 are measured
with PET,whereas DAT levels have been measured with
both PET and single photon emission computed tomog-
raphy (SPECT).All three targets (DOPA decarboxy-
lase,DAT,and VMAT2) are clearly biomarkers for DA
neurotransmission (Table I). Representative images in
PD patients and healthy subjects are shown in Figure 1.
Because they are biomarkers of DA neurotransmission,
the imaging of these targets has clear utility in the study
of the pathophysiology of PD.For example,imaging has
demonstrated the following:
•The known loss of DA innervation in PD.
•A negative correlation between the brain imaging
measurement and symptom severity in groups of
patients.
•The increasing progression of symptoms over time
within individual subjects.
At least two of these targets (DA synthesis and DAT)
have been shown to have modest diagnostic specificity.
That is, imaging of these two targets can clearly distin-
guish PD from benign senile tremor,but has marginal,if
any, utility to distinguish idiopathic PD from other
“parkinsonisms,”such as multisystem atrophy and stria-
tonigral degeneration. All three targets have demon-
strated significant “reserve function”in brain,such that
>50% loss of the target is required for the onset of clin-
ical symptoms. Serial studies of DA synthesis and DAT
levels in individual patients have shown about 10% loss
per annum in the early stages of the disease.As a rough
back-extrapolation, these results suggest that the pre-
clinical phase of the disease is ~5 years before the pres-
ence of symptoms adequate to make the diagnosis of PD
(ie, 50%/10% per annum = 5 years).Taken as a whole,
these results suggest imaging of DA neurotransmission
in PD may have at least two important clinical applica-
tions:
• Diagnosis in both clinical and preclinical phases.
•A biomarker for the efficacy of agents designed to
slow progression of the disease, ie, neuroprotective
agents.
Significant controversy surrounds the utility of imaging
to provide a “biomarker for efficacy”(ie,a surrogate end
point) for a potential neuroprotective agent. On first
consideration, it seems obvious that DA imaging is a
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Table I. Three targets for imaging dopamine (DA) neurotransmission in
Parkinson’s disease. DOPA, dihydroxyphenylalanine.
DOPA decarboxylase DOPA converting enzyme
DAT Dopamine transmitter
VMAT2 Vesicular monoamine transporter, type 2useful end point in a clinical study and provides a useful
surrogate for clinical efficacy.However,this may not be
the case.For example,a false-positive imaging end point
could result from an agent that slows the loss of the tar-
get, but has no clinically significant effect for the
patient’s symptomatology.Such a result may be the case
for a study of SPECT DAT imaging in patients with
pramipexole,where DAT loss was slower in the experi-
mental group, but with no clinically significant differ-
ences between groups.
1 One possible interpretation of
these results is that pramipexole has odd effects on DAT
levels, but is not a good measure of overall DA neuro-
transmission. Even more dramatic examples of a false-
positive surrogate end point exist. For example, the
antiarrhythmic agents flecainide and encainide were
evaluated with electrocardiogram (ECG) as their “sur-
rogate end point,” since agents that decrease ECG
arrhythmias must certainly help the patient. In fact,
these medications decreased arrhythmias, but, after
approval by the Federal Drug Administration (FDA),
were found to be associated with elevated cardiac mor-
tality.
2 This example surely shows the need to validate
surrogate end points,lest the treatment is found to cure
the disease and kill the patient! 
In the summer of 2003, the National Institutes of
Neurological Disorders and Stroke organized a panel of
experts with various backgrounds (including PD, imag-
ing, and regulatory affairs) to assess the utility of DA
imaging in PD.The consensus of this group was that DA
imaging of these three targets provide useful biomark-
ers to study pathophysiology,but that additional studies
are needed for them to be accepted by the field and the
FDA as validated surrogate end points.Enthusiasm was
strong for additional prospective studies to be per-
formed by academic researchers, often in collaboration
with industry and with input from regulatory authorities
such as the FDA.
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Figure 1. Representative radiotracer images of Parkinson’s disease (PD)
patients and healthy subjects. A. Single photon emission com-




B. Positron emission tomography (PET) images of DA synthesis
with [
18F]fluorodopa (FDOPA). C. PET images of vesicular
monoamine transporter, type 2 (VMAT2) with [
11C]dihydrotetra-
benazine. These images were acquired in PD patients with rela-
tively early onset of disease and compared to age-matched healthy
subjects. The color scale is slightly different for the three radio-
ligands. Nevertheless, all three imaging agents show a dramatic
and similar loss (~50%) of striatal uptake in PD patients compared
to the healthy subjects. 
A is from John Seibyl, MD (Institute for Neurodegenerative Disorders,
New Haven, CT). 
B is from David Eidelberg, MD (North Shore-Long Island Jewish Research
Institute, Manhasset, NY). 
C is from Kirk Frey, MD, PhD (University of Michigan at Ann Arbor, Ann
Arbor, Mich).
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